



SHAREABLE PDF

H2020 funding for respiratory research: scaling up for the prevention and treatment of lung diseases

Constantine I. Vardavas^{1,2}, Christina N. Kyriakos ^{1,2}, Esteve Fernández ³, Panagiotis Bamidis⁴, Kamran Siddiqi ^{5,6}, Niels H. Chavannes⁷, R.M.J.J. van der Kleij⁷, Gary Parker⁸, Cornel Radu-Loghin², Brian Ward⁹ and Karim Berkouk¹⁰

Affiliations: ¹School of Medicine, University of Crete, Heraklion, Greece. ²European Network for Smoking and Tobacco Prevention, Brussels, Belgium. ³WHO Collaborating Center for Tobacco Control, Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, University of Barcelona, L'Hospitalet de Llobregat, Catalonia, Spain. ⁴Lab of Medical Physics, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. ⁵Dept of Health Sciences, The University of York, York, UK. ⁶Hull-York Medical School, York, UK. ⁷Dept of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands. ⁸Global Alliance for Chronic Diseases, London, UK. ⁹European Respiratory Society, EU Affairs, Brussels, Belgium. ¹⁰European Commission, Directorate General for Research and Innovation, Health Directorate, Brussels, Belgium.

Correspondence: Constantine I. Vardavas, Laboratory of Toxicology, Faculty of Medicine, University of Crete, Heraklion, Greece. E-mail: vardavas@tobcontrol.eu



@ERSpublications

This European Lung Corner article summarises five key messages for future research and practice in preventing and treating lung diseases based on outcomes and perspectives from five Horizon 2020 projects <http://bit.ly/2YCJV5N>

Cite this article as: Vardavas CI, Kyriakos CN, Fernández E, *et al.* H2020 funding for respiratory research: scaling up for the prevention and treatment of lung diseases. *Eur Respir J* 2019; 54: 1901417 [<https://doi.org/10.1183/13993003.01417-2019>].

This single-page version can be shared freely online.

Respiratory diseases represent a significant public health challenge, in terms of disability and premature mortality, and also direct healthcare costs, drugs prescribed and the indirect costs related to lost productivity [1].